Skip to main content
SpringerLink
Log in

Hypertension and Cardiovascular Disease

  • Chapter
The Diabetic Kidney

Part of the book series: Contemporary Diabetes ((CDI))

Abstract

Type 2 diabetes mellitus (DM) is increasing exponentially; more than 18 million Americans are currently diagnosed, of which more than approx 73% have concomitant hypertension (HTN) (1). Notably, at the time of diagnosis of diabetes, HTN is present in 50% of diabetic patients (2). The presence of diabetic nephropathy (DN) and its clinical hallmark, microalbuminuria (MAU), with concommittant HTN accelerates progression to renal and cardiovascular disease (CVD). CVD risk progresses as DN progresses into chronic kidney disease (CKD) and finally end-stage renal disease (ESRD) requiring renal replacement therapy. Thus, it is then imperative to understand the close relationship that progressive DN has with HTN and concomitant advancing CVD risk. Primary preventive strategies are important to not only prevent DN, but to slow progression once it is present.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. McFarlane S, Gizycki HV, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718–723.

    Article  PubMed  Google Scholar 

  2. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86(2):713–718.

    Article  PubMed  CAS  Google Scholar 

  3. Couser WG, Johnson RJ. Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 1994;23:193–198.

    PubMed  CAS  Google Scholar 

  4. Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. J Am Med Assoc 2002;288:2579–2588.

    Article  CAS  Google Scholar 

  5. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995;44:1139–1146.

    Article  PubMed  CAS  Google Scholar 

  6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–820.

    Article  PubMed  CAS  Google Scholar 

  7. Setter SM, Campbell RK, Cahoon CJ. Biochemical pathways for microvascular complications of diabetes mellitus. Ann Pharmacother 2003;37:1858–1866.

    Article  PubMed  CAS  Google Scholar 

  8. Tilton RG. Diabetic Vascular Dysfunction: Links to glucose-induced reductive stress and VGEF. Microscopic Res Tech 2002;57:390–407.

    Article  CAS  Google Scholar 

  9. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315–1321.

    Article  PubMed  CAS  Google Scholar 

  10. Doi T, Vlassara H, Kirstein M, et al. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1992;89:2873–2877.

    Article  PubMed  CAS  Google Scholar 

  11. Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17,810–17,814.

    Article  PubMed  CAS  Google Scholar 

  12. Sakaguchi T, Yan SF, Yan SD, et al. Central Role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003;111:959–972.

    Article  PubMed  CAS  Google Scholar 

  13. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end-products (RAGE)-mediated neurite outgrowth and activation of NK-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999;274:199,919–199,924.

    Article  Google Scholar 

  14. Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end productprotein crosslinks. Arch Biochem Biophys 2003;282:F975–F980.

    Google Scholar 

  15. Sowers JR. Hypertension, Angiotensin II, and Oxidative Stress. N Engl J Med 2002;346:1999–2001.

    Article  PubMed  Google Scholar 

  16. Scivittaro V, Ganz MB, Weiss MF. AGE’s induce oxidative stress and activate protein kinase C-beta (III) in neonatal mesangial cells. Am J Physiol Renal Physiol 2000;278:F676–F683.

    PubMed  CAS  Google Scholar 

  17. Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelialmyofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001;108:1853–1863.

    Article  PubMed  CAS  Google Scholar 

  18. Frank JG. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005;115:500–508.

    Article  CAS  Google Scholar 

  19. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:84–844.

    Google Scholar 

  20. Kitada H, Tanaka M, Takemura Y, et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003;52:2603–2614.

    Article  PubMed  CAS  Google Scholar 

  21. Jones SA, Hancock JT, Jones OT, et al. The expression of NADPH-oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. J Am Soc Nephrol 1995;5:1483–1491.

    PubMed  CAS  Google Scholar 

  22. Tylicki L, Rutkowski B, Horl WH. Antioxidants: a possible role in kidney protection. Kidney Blood Press Res 2003;26:303–314.

    Article  PubMed  CAS  Google Scholar 

  23. Igashari M, Wakasaki H, Takahora N, et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999;103:185–195.

    Google Scholar 

  24. Kaya D, Jirousek MR, Lin YW, et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100:115–126.

    Article  Google Scholar 

  25. Way KJ, Isshiki K, Suzama K, et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002;51:2709–2718.

    Article  PubMed  CAS  Google Scholar 

  26. Kaya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14:439–447.

    Google Scholar 

  27. Kelly DJ, Zhang Y, Hepper C, et al. Protein kinase C-beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003;52:512–518.

    Article  PubMed  CAS  Google Scholar 

  28. Blendea MC, Jacobs D, Stump C, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 2005;288:E353–E359.

    Article  PubMed  CAS  Google Scholar 

  29. McFarlane SI, Sowers JR. Aldosterone function in diabetes mellitus: Effects on cardiovascular and renal disease. J Clin Endocrinol Metab 2003;88:516–523.

    Article  PubMed  CAS  Google Scholar 

  30. Sowers JR, Beck F, Waters D, et al. Studies of rennin activation and regulation of aldosterone and 18-hydroxycorticosterone biosynthesis in hyporeninemic, hypoaldosteronism. J Clin Endocrinol Metab 1985;61:60–67.

    Article  PubMed  CAS  Google Scholar 

  31. Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002;40:781–788.

    Article  PubMed  CAS  Google Scholar 

  32. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002;7:35–43.

    Article  PubMed  Google Scholar 

  33. Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003;16(11):41S–45S.

    Article  PubMed  Google Scholar 

  34. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion-a predictor of risk of cardiovascular disease. A prospective 10 year follow-up of middle-aged non-diabetic normal and hypertensive men. Am J Hypertens 1996;9:770–778.

    Article  PubMed  CAS  Google Scholar 

  35. Dineen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997;157:1413–1418.

    Article  Google Scholar 

  36. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of Chronic Kidney Disease: a position statement of the National Kidney Foundation (NKF) and the national institute of Diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003;42:617–622.

    Article  PubMed  Google Scholar 

  37. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney disease outcome quality initiative. Am J Kidney Dis 2002;39:S1–S246.

    Google Scholar 

  38. Bakris GL, Walsh MF, Sowers JR. Endothelium/mesangium interactions: role of insulin-like growth factors. In: Sowers JR, ed. Endocrinology of the vasculature. Humana, Totowa NJ, 1996,341–356.

    Google Scholar 

  39. Arun CS, Stoddart J, Mackin P, et al. Significance of microalbuminuria in long-duration type 1 diabetes. Diabetes Care 2003;26:2144–2149.

    Article  PubMed  Google Scholar 

  40. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.

    Article  PubMed  CAS  Google Scholar 

  41. Sowers JR. Insulin Resistance and Hypertension. Am J Physiol Heart Circ Physiol 2004;286(5):H1597–H1602.

    Article  PubMed  CAS  Google Scholar 

  42. Bianchi S, Bigazzi R, Quinones G, et al. Insulin Resisitance in microalbuminuric hypertension: sites and mechanisms. Hypertension 1995;57:1803–1817.

    Google Scholar 

  43. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of diabetes: the atherosclerosis risk in communities study. Diabetes 2003;52:1799–1805.

    Article  PubMed  CAS  Google Scholar 

  44. Weisberg SP, McCann D, Desnai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796–1808.

    Article  PubMed  CAS  Google Scholar 

  45. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24(3):278–301.

    Article  PubMed  CAS  Google Scholar 

  46. Tan A, Kuppuswamy S, Whaley-Connell A, Romayne L, Sowers JR. “Recommendations for Special Populations: the Treatment of Hypertension in Diabetes Mellitus.” Endocrinologist 2004;6:368–381.

    Article  Google Scholar 

  47. Stas S, El-Atat F, Sowers JR. Pathogenesis of Hypertension in Diabetes. Rev Endocr Metab Disord 2005;5:221–225.

    Article  Google Scholar 

  48. Sowers JR, Frolich ED. Insulin and Insulin Resistance: impact on blood pressure and Cardiovascular Disease. Med Clin North Am 2004;88:63–82.

    Article  PubMed  CAS  Google Scholar 

  49. Sowers JR, Stump C. Insights into the biology of diabetic vascular disease: What’s new? Am J Hypertens 2004;17(11):S2–S6.

    Article  CAS  Google Scholar 

  50. Berne C, Fagius J, Pollare T, Hjemdahl P. The sympathetic response to euglycaemic hyperinsulinaemia. Diabetologia 1992;35:873–879.

    Article  PubMed  CAS  Google Scholar 

  51. Aras R, Sowers JR, Arora R. The Proinflammatory and Hypercoaguable State of Diabetes Mellitus. Rev Cardiovasc Med 2005;10(6):1–15.

    Google Scholar 

  52. Stehouwer CDA. Endothelial Dysfucntion in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004;19:778–781.

    Article  PubMed  Google Scholar 

  53. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003 289(19)2560–2571.

    Article  PubMed  CAS  Google Scholar 

  54. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with Hypertension and Diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646–661.

    PubMed  CAS  Google Scholar 

  55. World Health Organization, International society of Hypertension Writing Group.2003 World Health Organization ( WHO)/International society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21(11):1983–1992.

    Article  Google Scholar 

  56. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  57. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000;321:412–419.

    Article  CAS  Google Scholar 

  58. Curb JD, Pressel SL, Cutler J, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886–1892.

    Article  PubMed  CAS  Google Scholar 

  59. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. The Systolic Hypertension in Europe Trial investigators: effect of calcium-channel blockage in older patients with diabetes and systolic hypertension. N Engl J Med 199;340:677–684.

    Google Scholar 

  60. Wong ND, Pio JR, Franklin SS, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003;91(12):1421–1426.

    Article  PubMed  Google Scholar 

  61. McFarlane S, Gizycki HV, Winer N, et al. Control of Cardiovascular Risk Factors in Patients With Diabetes and Hypertension at Urban Academic Medical Centers. Diabetes Care 2002;25:718–723.

    Article  PubMed  Google Scholar 

  62. Gaede P, Vedel P, Larsen N, et al. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med 2003;348(5):383–393.

    Article  PubMed  Google Scholar 

  63. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611–616.

    Article  PubMed  CAS  Google Scholar 

  64. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001;24:2091–2096.

    Article  PubMed  CAS  Google Scholar 

  65. Yosuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153.

    Article  Google Scholar 

  66. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253–259.

    Article  Google Scholar 

  67. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The Effect Of Angiotensin-Converting-Enzyme Inhibition On Diabetic Nephropathy. The Collaborative Study Group. N Engl J Med 1993;329(20):1456–1462

    Article  PubMed  CAS  Google Scholar 

  68. Euclid Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787–1792.

    Article  Google Scholar 

  69. Bakris GL, Smith AC, Richardson DJ, et al. Impact of ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomized, multi-center pilot study. J Hum Hypertens 2002;16:185–191.

    Article  PubMed  CAS  Google Scholar 

  70. Ravid M, Archmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus; A 7-year follow-up study. Arch Intern Med 1996;156:286–289.

    Article  PubMed  CAS  Google Scholar 

  71. Remenenti P, Fassi A, Parnova I, et al. Preventing microalbuminuira in type 2 diabetes. N Engl J Med 2004;351(19):1941–1951.

    Article  Google Scholar 

  72. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-Receptor Blockade versus Converting-Enzyme Inhibition in Type 2 Diabetes and Nephropathy. N Engl J Med 2004;351(19):1952–1961.

    Article  PubMed  CAS  Google Scholar 

  73. Deedwania PC. Hypertension and diabetes: New therapeutic options. Arch Intern Med 2000;160(11):1585–1594.

    Article  PubMed  CAS  Google Scholar 

  74. Larochelle P, Clack JM, Marbury T, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol 1997;80:1613–1615

    Article  PubMed  CAS  Google Scholar 

  75. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):1004–1010.

    Article  PubMed  CAS  Google Scholar 

  76. Zanchetti A, Ruilope LM. Antihypertensive treatement in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002;20(11)2099–2110.

    Article  PubMed  CAS  Google Scholar 

  77. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.

    Article  Google Scholar 

  78. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2001;349:1893–1906.

    Article  Google Scholar 

  79. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163(13):1555–1565.

    Article  PubMed  Google Scholar 

  80. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870–878.

    Article  PubMed  CAS  Google Scholar 

  81. Viberti GC, Wheelden NM, For the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Inverstigators: Micoralbuminuira reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672–678.

    Article  PubMed  CAS  Google Scholar 

  82. Mogensen CE, Neldam S, Tikkanen I, et al. Randomized controlled trial of dual blockade of renninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candersartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440–1444.

    Article  PubMed  CAS  Google Scholar 

  83. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens. 2002;20(1):125–130.

    Article  PubMed  CAS  Google Scholar 

  84. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002;288(23):2981–2997.

    Article  Google Scholar 

  85. Black HR, Elliot WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension 2001;37:12–18.

    PubMed  CAS  Google Scholar 

  86. American Diabetes Association. Hypertension Management in Adults With Diabetes: clinical practice recommendations 2004. Diabetes Care 2004;27(1):S65–S67

    Article  Google Scholar 

  87. Koyama Y, Kodama K, Suziki M, Harano Y. Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens 2002;15:927–931.

    Article  PubMed  CAS  Google Scholar 

  88. Zanella MT, Kohlmann O, Ribero AB. Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001,38:705–708.

    PubMed  CAS  Google Scholar 

  89. Black HR, Elliott WJ, Grandits G, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. J Am Med Assoc 2003;289(16):2073–2082.

    Article  CAS  Google Scholar 

  90. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. J Am Med Assoc 2003;290(21):2805–2816.

    Article  CAS  Google Scholar 

  91. Brenner Bm, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.

    Article  PubMed  CAS  Google Scholar 

  92. Birkenhager WH, Staessen JA, Gasowski J, de Leeuw PW. Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial. J Nephrol 2000;13(3):232–237.

    PubMed  CAS  Google Scholar 

  93. Jacob S, Balletshofer B, Henriksen EJ, et al. Beta-blocking agents in patients with insulin resistance: effects of vasodialting beta-blockers. Blood Press 1999;8:261–268.

    Article  PubMed  CAS  Google Scholar 

  94. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-depenedent diabetes mellitus and hypertension. A randomised, controlled trial. Ann Intern Med 1997;126:955–959.

    PubMed  CAS  Google Scholar 

  95. Fassbinder W, Quarder O, Waltz A. Treatment with Carvedilol is associated with a significant reduction in microalbuminuria: a multi-center, randomized study. Int J Clin Pract 1999;53:519–520.

    PubMed  CAS  Google Scholar 

  96. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001;357:1385–1390.

    Article  PubMed  CAS  Google Scholar 

  97. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): a randomized controlled trial. Lancet 2003;362:7–13.

    Article  PubMed  CAS  Google Scholar 

  98. American Diabetes Association. Hypertension Management in Adults With Diabetes: clinical practice recommendations 2004. Diabetes Care 2004;27(1):S65–S67.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Missouri- Columbia School of Medicine and Divisions of Endocrinology and Nephrology, Harry S. Truman VA Medical Center, Columbia, MO

    Adam Whaley-Connell DO, Kurt Sowers MD & James R. Sowers MD

Authors
  1. Adam Whaley-Connell DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kurt Sowers MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James R. Sowers MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, MI

    Pedro Cortes MD

  2. Department of Internal Medicine M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus, Denmark

    Carl Erik Mogensen MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Whaley-Connell, A., Sowers, K., Sowers, J.R. (2006). Hypertension and Cardiovascular Disease. In: Cortes, P., Mogensen, C.E. (eds) The Diabetic Kidney. Contemporary Diabetes. Humana Press. https://doi.org/10.1007/978-1-59745-153-6_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-153-6_28

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-624-5

  • Online ISBN: 978-1-59745-153-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation